HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment
Open Access
- 9 December 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (49), 19183-19187
- https://doi.org/10.1073/pnas.0805514105
Abstract
The overlapping histological and biochemical features underlying the beneficial effect of deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated molecular link among dystrophin, NO signaling, and the histone deacetylases (HDACs). Higher global deacetylase activity and selective increased expression of the class I histone deacetylase HDAC2 were detected in muscles of dystrophin-deficient MDX mice. In vitro and in vivo siRNA-mediated down-regulation of HDAC2 in dystrophic muscles was sufficient to replicate the morphological and functional benefits observed with deacetylase inhibitors and NO donors. We found that restoration of NO signaling in vivo, by adenoviral-mediated expression of a constitutively active endothelial NOS mutant in MDX muscles, and in vitro, by exposing MDX-derived satellite cells to NO donors, resulted in HDAC2 blockade by cysteine S-nitrosylation. These data reveal a special contribution of HDAC2 in the pathogenesis of Duchenne muscular dystrophy and indicate that HDAC2 inhibition by NO-dependent S-nitrosylation is important for the therapeutic response to NO donors in MDX mice. They also define a common target for independent pharmacological interventions in the treatment of Duchenne muscular dystrophy.Keywords
This publication has 30 references indexed in Scilit:
- Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology inmdxmiceThe FASEB Journal, 2007
- Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progressionThe FASEB Journal, 2007
- Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapyProceedings of the National Academy of Sciences, 2007
- Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophyJournal of Cell Science, 2006
- Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitorsNature Medicine, 2006
- How corticosteroids control inflammation: Quintiles Prize Lecture 2005British Journal of Pharmacology, 2006
- Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusionThe Journal of cell biology, 2006
- A Nitric Oxide Signaling Pathway Controls CREB-Mediated Gene Expression in NeuronsMolecular Cell, 2006
- Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylationGenes & Development, 1999
- Histone Deacetylases and SAP18, a Novel Polypeptide, Are Components of a Human Sin3 ComplexCell, 1997